Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -20.62% is 78% above its 5-year average of -92.65%, near the high end of its 5-year range (-163.30%–10.95%).
4.64% below its 12-month average of -19.71%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -22.04%.
OPERATING MARGIN
-20.62%
OPERATING MARGIN AVG TTM
-19.71%
OPERATING MARGIN AVG 3Y
-69.99%
OPERATING MARGIN AVG 5Y
-92.65%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.64%
CURRENT VS 3Y AVG
+70.54%
CURRENT VS 5Y AVG
+77.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 384 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Adaptive Biotechnologies Corporation
Market Cap
$4.78B
Operating Margin
-20.62%
TTM Avg
-19.71%
3Y Avg
-69.99%
5Y Avg
-92.65%
Market Cap
$4.81B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.92B
Operating Margin
-8739.34%
TTM Avg
-5186.54%
3Y Avg
-3135.16%
5Y Avg
-2237.88%
Market Cap
$5.02B
Operating Margin
10.90%
TTM Avg
-12.82%
3Y Avg
-40.85%
5Y Avg
-40.85%
Market Cap
$5.20B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-101.20%
5Y Avg
-276.55%
Market Cap
$5.20B
Operating Margin
12.75%
TTM Avg
11.82%
3Y Avg
10.28%
5Y Avg
7.77%
Market Cap
$4.34B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.27B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-174.05%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.78B | -20.62% | -19.71% | -69.99% | -92.65% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | 0.00% | 0.00% | 0.00% | 0.00% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | -8739.34% | -5186.54% | -3135.16% | -2237.88% |
| BillionToOne, Inc. (BLLN)vs › | $5.02B | 10.90% | -12.82% | -40.85% | -40.85% |
| Erasca, Inc. (ERAS)vs › | $5.11B | 0.00% | 0.00% | 0.00% | 0.00% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.20B | 0.00% | 0.00% | -101.20% | -276.55% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.20B | 12.75% | 11.82% | 10.28% | 7.77% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.34B | 0.00% | 0.00% | 0.00% | 0.00% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.27B | 0.00% | 0.00% | 0.00% | -174.05% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.21B | -288.98% | -690.34% | -489.97% | -306.42% |
Gross Margin
75.4%
Operating Margin
-20.6%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -22.04% |
| 2026-03-31 | -27.10% |
| 2025-12-31 | -17.82% |
| 2025-09-30 | 10.95% |
| 2025-06-30 | -42.52% |
| 2025-03-31 | -56.45% |
| 2024-12-31 | -71.30% |
| 2024-09-30 | -70.27% |
| 2024-06-30 | -109.56% |
| 2024-03-31 | -116.45% |
| 2023-12-31 | -155.22% |
| 2023-09-30 | -134.38% |
| 2023-06-30 | -97.74% |
| 2023-03-31 | -151.92% |
| 2022-12-31 | -70.99% |
| 2022-09-30 | -94.98% |
| 2022-06-30 | -120.25% |
| 2022-03-31 | -163.30% |
| 2021-12-31 | -162.39% |
| 2021-09-30 | -142.71% |
| 2021-06-30 | -129.24% |
| 2021-03-31 | -107.38% |
| 2020-12-31 | -146.56% |
| 2020-09-30 | -140.88% |
| 2020-06-30 | -175.86% |
| 2020-03-31 | -165.57% |
| 2019-12-31 | -99.91% |
| 2019-09-30 | -69.28% |
| 2019-06-30 | -72.75% |
| 2019-03-31 | -158.26% |
| 2018-12-31 | -82.27% |
| 2018-09-30 | -53.30% |
| 2018-06-30 | -115.08% |
| 2018-03-31 | -135.23% |
